Jupiter Neurosciences lands U.S. rights to ALA-002 in deal worth up to $100M

Jupiter Neurosciences signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based candidate with FDA Novel Chemical Entity designation. The deal gives the clinical-stage biotech a second CNS program alongside its Parkinson’s asset and could speed development under a more favorable U.S. regulatory backdrop.

Why it matters: - The agreement turns Jupiter Neurosciences from a single-program company into a dual clinical-stage central nervous system developer. - ALA-002 adds a second independent development path alongside Jupiter Neurosciences’ Parkinson’s program. - The deal gives Jupiter perpetual exclusive U.S. rights to an FDA-designated Novel Chemical Entity with potential regulatory and commercial protection. - The transaction could create a U.S. commercialization opportunity in psychedelic therapeutics if development and approval milestones are achieved.

What happened: - Jupiter Neurosciences entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for ALA-002. - The agreement was announced July 22, 2026. - The rights are perpetual and exclusive in the United States. - Jupiter said the transaction has a potential value of up to $100 million, including milestone payments.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. - The company owes $3.3 million more if ALA-002 reaches Phase 3 first patient in. - Jupiter faces a $20 million regulatory milestone if the U.S. Food and Drug Administration approves an NDA. - Commercial milestones total $73.3 million, tied to cumulative U.S. net sales of $333 million, $1 billion and $2 billion. - Jupiter will also pay a 3% royalty on net sales, starting after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation with FDA Novel Chemical Entity designation. - The NCE status provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter says ALA-002 was engineered to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving pro-social and therapeutic effects. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - PharmAla will continue manufacturing ALA-002 for Jupiter under commercial terms to be negotiated. - The company said that could accelerate development timelines. - Jupiter said the deal strengthens the pipeline by adding both its natural resveratrol program and a Novel Chemical Entity. - Jupiter’s lead program, JOTROL™, is a proprietary enhanced-bioavailability resveratrol formulation now in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia™, a consumer longevity supplement. - The company said ALA-002 targets a U.S. psychedelic therapeutics market estimated at $3 billion in 2024 and growing to $8 billion by 2030. - The release said the candidate addresses treatment-resistant PTSD, anxiety and related neuropsychiatric conditions.

Between the lines: - The deal is structured to limit near-term cash outlay while giving Jupiter access to a higher-upside asset. - The stock component means PharmAla has continuing exposure to Jupiter’s share performance. - Jupiter is positioning ALA-002 as a strategic fit for U.S. brain-therapy development while PharmAla remains focused outside the United States. - Management linked the transaction to a federal executive order signed April 18, 2026, that directs FDA and DEA efforts to expand access to investigational psychedelic therapies. - The order includes a Right to Try pathway, Commissioner’s National Priority Vouchers and $50 million in ARPA-H funding for psychedelic medicine programs. - Those policy developments may help shorten development timelines, but the release also notes the usual clinical, regulatory and financing risks. - Jupiter said it has recently added two board experts, Tomas Philipson and Andrew Cutler, as it builds in psychedelic medicines.

What's next: - Jupiter and PharmAla still need to complete the transaction’s closing conditions. - The companies will negotiate commercial manufacturing terms for ALA-002 supply. - Jupiter will focus on advancing both ALA-002 and JOTROL toward clinical and regulatory milestones. - Future value for the deal depends on clinical progress, FDA review, sales performance and royalty generation. - Jupiter said the next 12 months will be transformative for the company.

The bottom line: - Jupiter just bought itself a second shot on goal in CNS, and it did so with a structure that ties most of the payout to development and commercial success.